en · de · es
creatine-notes.peptides8425.com › Info › Background And Development History — Worked Examples

Background And Development History — Worked Examples

By Editorial Desk · published 2025-10-18 · last reviewed 2025-11-22 · Info

Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-11-22. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Development History

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Regulation and Detection Context

Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideDerived from C-terminal region of human growth hormone
Approximate molecular massAbout 1.8 kDaVaries with sequence length and counterions
Confirmed receptor targetNone establishedNo confirmed growth hormone receptor agonism
Reported in vitro activityLipolysis stimulation and lipogenesis inhibitionObserved mainly in adipocyte models; human relevance uncertain
Regulatory statusNot approved as a drug in major marketsMay be treated differently across jurisdictions; not a recognized dietary ingredient in some countries

Background And Research Context

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

Related pages on this site

Background and Molecular Identity

Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Supporting material

== Synthesis == First, 2-(o-chlorobenzoylamino)-5-bromo-2-chlorobenzophenone is prepared by acylation of p-bromoaniline with o-chlorobenzoic acid acyl chloride in the presence of a zinc chloride catalyst. This is hydrolysed with aqueous sulfuric acid to yield 2-amino-5-bromo-2'-chlorobenzophenone, which is then acylated with hydrochloride of aminoacetic acid acyl chloride in chloroform to form 2-(aminomethylkarbonylamino)-5-bromo-2-chlorobenzophenone hydrochloride, which is converted to a base with aqueous ammonia and then thermally cyclized to bromodihydrochlorophenylbenzodiazepine (phenazepam). Hydrochloride of aminoacetic acid acyl chloride is prepared by chemical treating glycine with phosphorus pentachloride (PCl5) in chloroform.

=== Generic forms === Generic forms of oral selegiline are available in the United States. However, generic forms of the orally disintegrating tablet and the transdermal patch are not available in this country. The latter formulations of selegiline are very expensive, and this can be prohibitive to their use. There has been poor insurance coverage of the transdermal patch form for depression, with insurance companies often requiring patients to first fail to respond to one or two other antidepressants and to be responsible for larger copayments. It is expected that generics of the transdermal patch will become available at some point in the future.

Hazard research is published: several dietary habits and products including teabags are linked to PFAS intake (4 Feb), an additional three billion people may face water scarcity by 2050 when river pollution is considered, an aspect neglected by prior assessments (6 Feb), HPV infection linked to higher cardiovascular mortality (7 Feb), researchers use simulations to develop an early-warning signal for a potential collapse of the atlantic meridional overturning circulation (AMOC) and suggest it indicates the AMOC is "on route to tipping" (9 Feb), researchers report the H5N1 bird flu virus may be changing and adapting to infect more mammals (12 Feb), researchers report how compounding disturbances could trigger unexpected ecosystem transitions in the Amazon rainforest (14 Feb), harmful chlormequat is found in ~80% of U.S. adult urine samples, rising during 2023, and in oat-based foods widely thought to be healthy (15 Feb), excess amounts of widely-supplemented niacin (B3) are linked to cardiovascular risk (19 Feb), a review concludes available evidence on the use of puberty blockers and cross-sex hormones in minors with gender dysphoria is very limited and based on only a few studies with small numbers which have problematic methodology and quality, warning about their use outside of clinical studies or research projects after careful risk-benefit evaluation (27 Feb).

== Controversial terminology == A toxic heavy metal is a common but misleading term for a metal-like element noted for its potential toxicity. Not all heavy metals are toxic and some toxic metals are not heavy. The International Union of Pure and Applied Chemistry (IUPAC), which standardizes nomenclature, says the term "'heavy metals' is both meaningless and misleading". The IUPAC report focuses on the legal and toxicological implications of describing "heavy metals" as toxins when there is no scientific evidence to support a connection. The density implied by the adjective "heavy" has almost no biological consequences, and pure metals are rarely the biologically active substance. This characterization has been echoed by numerous reviews. The most widely used toxicology textbook, Casarett and Doull's Toxicology, uses "toxic metal", not "heavy metals". Nevertheless many scientific and science-related articles, including medical texts, continue to use "heavy metal" as a term for toxic substances.

F−H···F− (161.5 kJ/mol (38.6 kcal/mol)), illustrated uniquely by HF2- O−H···N (29 kJ/mol (6.9 kcal/mol)), illustrated water-ammonia O−H···O (21 kJ/mol (5.0 kcal/mol)), illustrated water-water, alcohol-alcohol N−H···N (13 kJ/mol (3.1 kcal/mol)), illustrated by ammonia-ammonia N−H···O (8 kJ/mol (1.9 kcal/mol)), illustrated water-amide OH+3···OH2 (18 kJ/mol (4.3 kcal/mol)) The strength of intermolecular hydrogen bonds is most often evaluated by measurements of equilibria between molecules containing donor and/or acceptor units, most often in solution. The strength of intramolecular hydrogen bonds can be studied with equilibria between conformers with and without hydrogen bonds. The most important method for the identification of hydrogen bonds also in complicated molecules is crystallography, sometimes also NMR-spectroscopy. Structural details, in particular distances between donor and acceptor which are smaller than the sum of the van der Waals radii can be taken as indication of the hydrogen bond strength. One scheme gives the following somewhat arbitrary classification: those that are 63 to 167 kJ/mol (15 to 40 kcal/mol), 21 to 63 kJ/mol (5 to 15 kcal/mol), and 0 to 21 kJ/mol (0 to 5 kcal/mol) are considered strong, moderate, and weak, respectively. Hydrogen bonds involving C−H bonds are both very rare and weak.

Sources: en.wikipedia.org

Notes from published material

The first 7-Eleven store in Denmark was opened at Østerbro in Copenhagen on September 14, 1993. There are 185 stores, mostly in Copenhagen, Aarhus, Aalborg, and Odense, including two stores at Copenhagen Central Station. In Denmark, 7-Eleven had an agreement with Shell, with a nationwide network of Shell/7-Eleven service stations. This ended in 2024 when the national franchise operator Reitan Danmark did not renew the agreement and instead used their own brand of service station Uno-X. 7-Eleven also have an agreement with the Danish railway company DSB to have 7-Eleven stores at most S-train stations and other train stations. In 2022, 7-Eleven in Denmark suffered a widespread ransomware attack that caused all stores to temporarily close. 7-Eleven did not comply with the attacker's demands. No customer data was compromised in the attack. The three biggest 7-Eleven stores in terms of revenue in the world, are all located in Denmark. The top two stores are both located at Copenhagen Central Station and the third are located at Copenhagen Airport beyond security.

A recipe from 1909 adds onions and tomato sauce, and serves it with crisp potato straws, which are considered the traditional side dish for beef Stroganoff in Russia. The version given in the 1938 Larousse Gastronomique includes beef strips, and onions, with either mustard or tomato paste optional. After the fall of the Russian monarchy in 1917, the recipe was popularly served in the hotels and restaurants of China before the start of World War II. The first English cookbook to include a recipe for beef Stroganoff is Ambrose Heath's Good Food (1932). The dish came to Hong Kong in the late 1950s. In 1960s United States, several manufacturers introduced dehydrated beef stroganoff mixes, which were mixed with cooked beef and sour cream. It was also available freeze-dried for campers.

Ribonucleoproteins (RNPs): complexes made up of RNAs and RNA-binding proteins (RBPs) NHS-diazirine (SDA): a cell permeable crosslinking reagent. SDA contains two reactive groups - a diazirine and a succinimidyl ester. The reaction between succinimidyl esters and amine groups (e.g. lysine side chains) results in peptide bonds (or amide bonds). When exposed to UV light with a wavelength of 365 nm, an intermediate broadly reactive toward nucleotide riboses and bases is formed. As a result, proteins are crosslinked with RNA by the SDA linker. Mutational profiling (MaP): a method using reverse transcriptase with relaxed fidelity to incorporate modified residues at protein-RNA binding sites.

Hong Kong is a special administrative region of China. Situated on China's southern coast just south of Shenzhen, it consists of Hong Kong Island, Kowloon, and the New Territories. With 7.5 million residents in a 1,114-square-kilometre (430 sq mi) territory, Hong Kong is the fourth-most densely populated region in the world. Hong Kong was established as a colony of the British Empire after the Qing dynasty ceded Hong Kong Island in 1841–1842 as a result of losing the First Opium War. The colony expanded to the Kowloon Peninsula in 1860 and was further extended when the United Kingdom obtained a 99-year lease of the New Territories in 1898. Hong Kong was occupied by Japan from 1941 to 1945 during World War II. The territory was handed over from the United Kingdom to China in 1997. Hong Kong maintains separate governing and economic systems from those of mainland China under the principle of one country, two systems. Originally an area of farming and fishing villages, Hong Kong is now one of the world's most significant financial centres. Hong Kong is the world's third-ranked global financial centre behind New York City and London, the ninth-largest exporter, and the eighth-largest importer in the world. Its currency, the Hong Kong dollar, is the ninth-most traded currency globally. Home to the third-highest number of billionaires of any city in the world, Hong Kong has the second largest number of ultra high-net-worth individuals. The city has one of the highest per capita incomes, although severe income inequality still exists among the population.

=== Playwright === Shawn's early plays, such as Marie and Bruce (1978), portrayed emotional and sexual conflicts in an absurdist style, with language both lyrical and violent. In a conversation with Andre Gregory, parts of which were used to create My Dinner with Andre, Shawn said these plays depicted "my interior life as a raging beast." Critical response was extremely polarized: some critics hailed Shawn as a major writer, while John Simon called Marie and Bruce "garbage" and Shawn "one of the unsightliest actors in this city." His 1977 play A Thought in Three Parts caused controversy in London when the production was investigated by a vice squad and attacked in Parliament after allegations of pornographic content. Shawn received an Obie Award for playwrighting in 1975, for Our Late Night.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD9604 derived from?

AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.

Is AOD9604 approved as a medicine?

It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.

Does AOD9604 raise IGF-1 levels?

In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.

Is AOD-9604 banned in sport?

Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.

Network